Enable AccessibilityEnable Accessibility

Shire to Highlight Focus on Rare Disease Innovation at Investor Day

November 4, 2016

Company to discuss strength of its commercial portfolio and robust pipeline in rare diseases and specialized conditions.

Hematology and Immunology franchises and select, late-stage clinical programs to be featured

Lexington, Mass. – November 04, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it will host an Investor Day focused on its growth opportunities, commercial portfolio and innovative R&D pipeline on Thursday, November 10, 2016, from 8:30 a.m. to 2:30 p.m. EST in New York City. The Investor Day presentations will be broadcast via a live video and audio webcast. A replay of the webcast will be archived on the website following the presentation.

The details of the webcast are follows:

UK dial in: 0808 237 0036 or 020 3426 2889
US dial in: 1 877 841 4559 or 1 347 329 1282
Live video and audio webcast: shireinvestorday.com


Shire will provide an update to the investment community on the Company’s R&D strategy and pipeline, and highlight its progress in becoming the leading biotechnology company focused on rare diseases and highly specialized conditions. Members of Shire’s executive team will discuss the Company’s current business, platform for future growth, and further highlight the benefits gained through the Baxalta acquisition.

Shire will also educate investors on the opportunities and durability of the Company’s Hematology and Immunology franchises, as well as select late-stage programs in its robust pipeline including SHP621 in Eosinophilic Esophagitis (EoE); SHP647 for Inflammatory Bowel Disease (IBD); SHP620 (maribavir) for cytomegalovirus (CMV) infection in transplant recipient patients; SHP607 for Complications of Prematurity; SHP465 for Attention-Deficit/Hyperactivity Disorder (ADHD); and SHP643  for Hereditary Angioedema (HAE). No new material information will be disclosed.

Shire speakers to present include:

  • Flemming Ornskov, MD, MPH, Chief Executive Officer
  • Jeff Poulton, Chief Financial Officer
  • Phil Vickers, Ph.D., Head of Research & Development
  • Kim Stratton, Head of International Commercial
  • Perry Sternberg, Head of US Commercial
  • Howard Mayer, MD, Head of Clinical Development
  • Norman Barton, MD, Neuroscience Therapeutic Area Lead, Clinical Development
  • Wolfram Nothaft, MD, Therapeutic Area Head, Immunology

For further information please contact:

Investor Relations    
Sarah Elton-Farr [email protected] +44 1256 894157
Ian Karp [email protected] +1 781 482 9018
Robert Coates [email protected] +44 1256 894874
Lisa Adler [email protected] +1 617 588 8607
Debbi Ford [email protected]  +1 617 949 9083


Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.



Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:

  • Shire’s products may not be a commercial success;
  • increased pricing pressures and limits on patient access as a result of governmental regulations and market developments may affect Shire’s future revenues, financial condition and results of operations;
  • Shire conducts its own manufacturing operations for certain of its products and is reliant on third party contract manufacturers to manufacture other products and to provide goods and services. Some of Shire’s products or ingredients are only available from a single approved source for manufacture. Any disruption to the supply chain for any of Shire’s products may result in Shire being unable to continue marketing or developing a product or may result in Shire being unable to do so on a commercially viable basis for some period of time;
  • the manufacture of Shire’s products is subject to extensive oversight by various regulatory agencies. Regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, an increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • certain of Shire’s therapies involve lengthy and complex processes, which may prevent Shire from timely responding to market forces and effectively managing its production capacity;
  • Shire has a portfolio of products in various stages of research and development. The successful development of these products is highly uncertain and requires significant expenditures and time, and there is no guarantee that these products will receive regulatory approval;
  • the actions of certain customers could affect Shire’s ability to sell or market products profitably. Fluctuations in buying or distribution patterns by such customers can adversely affect Shire’s revenues, financial conditions or results of operations;
  • Shire’s products and product candidates face substantial competition in the product markets in which it operates, including competition from generics;
  • adverse outcomes in legal matters, tax audits and other disputes, including Shire’s ability to enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on the combined company’s revenues, financial condition or results of operations;
  • inability to successfully compete for highly qualified personnel from other companies and organizations;
  • failure to achieve the strategic objectives with respect to Shire’s acquisition of NPS, Dyax or Baxalta may adversely affect Shire’s financial condition and results of operations;
  • Shire’s growth strategy depends in part upon its ability to expand its product portfolio through external collaborations, which, if unsuccessful, may adversely affect the development and sale of its products;
  • a slowdown of global economic growth, or economic instability of countries in which Shire does business, as well as changes in foreign currency exchange rates and interest rates, that adversely impact the availability and cost of credit and customer purchasing and payment patterns, including the collectability of customer accounts receivable;
  • failure of a marketed product to work effectively or if such a product is the cause of adverse side effects could result in damage to Shire’s reputation, the withdrawal of the product and legal action against Shire;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire’s activities in the highly regulated markets in which it operates may result in significant legal costs and the payment of substantial compensation or fines;
  • Shire is dependent on information technology and its systems and infrastructure face certain risks, including from service disruptions, the loss of sensitive or confidential information, cyber-attacks and other security breaches or data leakages that could have a material adverse effect on Shire’s revenues, financial condition or results of operations;
  • Shire incurred substantial additional indebtedness to finance the Baxalta acquisition, which may decrease its business flexibility and increase borrowing costs;
  • difficulties in integrating Dyax or Baxalta into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all; and

other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission, including those risks outlined in “ITEM 1A: Risk Factors” in Shire’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2016.

All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.